白细胞介素-6与类风湿性关节炎

Interleukin-6 and rheumatoid arthritis

类风湿性关节炎(RA)是以关节滑膜炎为特征的自身免疫性疾病(AID),细胞因子(CK)贯穿RA的整个病程。重要的CK如TNF-α、白细胞介素-1β(IL-1β)在促进关节滑膜细胞增生和炎症进程中起举足轻重的作用。近年来,临床对RA的治疗主要以这些CK为靶点,然而TNF-α、IL-1β阻断剂只对部分患者有效,逐渐增多的不良反应如继发感染、恶性肿瘤的发生等也逐渐引起关注。白细胞介素-6(IL-6)的异常表达和失调与RA的病情密切相关,是RA发病的重要调控因子,阻断剂可能用于RA的临床治疗。

Rheumatoid arthritis（RA） is an autoimmune disease（AID） characterized by arthrosynovitis.Cytokines are involved in the whole course of the disease.Such important cytokines as TNF-α and IL-1β play a key role in the proliferation of synovial cells and progression of inflammation,and,therefore,have been taken as clinical therapeutic targets for RA in the recent years.The blocking agent of TNF-α or IL-1β is effective for only a few patients and the increasing adverse events it causes,such as infection and malignancy,are arousing more and more concern.The abnormal expression and imbalance of interleukin-6（IL-6） are closely associated with RA.IL-6 is an important regulatory factor for the pathogenesis of RA,and the blocking agent may be applied to the treatment of the disease.